Takeda to sell TachoSil surgical patch to Corza Health for 350m euros
[TOKYO] Takeda Pharmaceutical said on Wednesday it would sell its TachoSil surgical patch product to Corza Health for 350 million euros (S$563.7 million) as the Japanese company continues to divest non-core businesses.
TachoSil, a surgical patch used for bleeding control, delivered US$160 million in sales for Takeda in the fiscal year ended March 31, 2020, the company said in a release.
To reduce debt, Takeda has pledged to dispose of US$10 billion worth of non-core assets.
Takeda is focusing on five key business areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies.
REUTERS
GET BT IN YOUR INBOX DAILY
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Abbott beats quarterly profit estimates on strong medical device sales
Adidas shares surpass two-year high as 'terrace' sneaker trend boosts brand heat
LVMH’s first quarter sales growth slips to 3% on luxury slowdown
US Justice Department to file antitrust suit against Live Nation: WSJ
EU set to launch China probe on medical device procurement
Muji bets its minimalist retail will work for homes, hotels